Glycopyrronium Bromide is superior to Trihexyphenidyl for reducing drooling in children with cerebral palsy—An unregistered randomized controlled trial

Authors

  • Romana Akter Happy Junior Consultant (Paediatrics), Department of Paediatrics, Government Employee Hospital (Sarkari karmachari Hospital), Fulbaria, Dhaka, Bangladesh
  • Bithi Debnath Associate Professor, Department of Paediatric Neurology, National Institute of Neurosciences and Hospital, Dhaka, Bangladesh
  • Narayan Chandra Saha Professor and Head, Department of Paediatric Neurology, National Institute of Neurosciences and Hospital, Dhaka, Bangladesh
  • Seikh Azimul Hoque Professor, Department of Paediatrics, MAG Osmani Medical College, Sylhet, Bangladesh
  • Mosammat Shameem Ara Begum Assistant. Professor, Department of Paediatric Neurology, National Institute of Neurosciences and Hospital, Dhaka, Bangladesh
  • Soabraj Al Quiraishi Medical Officer, Neurology, National Institute of Neurosciences and Hospital, Dhaka, Bangladesh
  • Tithi Islam Junior consultant (Paediatrics), UHC, Saturia, Manikganj, Bangladesh
  • Taslima Sultana Junior Consultant (Paediatrics), Department of Paediatrics, Government Employee Hospital (Sarkari Karmachari Hospital), Fulbaria, Dhaka, Bangladesh

DOI:

https://doi.org/10.3329/jbcps.v44i1.87292

Keywords:

Cerebral Palsy, Drooling, Glycopyrronium bromide, Trihexyphenidyl, Children , Thomas Stonell and Greenberg drooling rating scale

Abstract

Background: Cerebral palsy is frequently associated with drooling or anterior sialorrhoea. This study was aimed to compare the efficacy of Glycopyrronium bromide and Trihexyphenidyl to reduce drooling in children with cerebral palsy (CP).

Materials and Methods: A single-centered, unregistered, randomized controlled trial was conducted from January to December 2022 on 100 children (aged 3–14 years) diagnosed with CP. The patients receiving conservative therapy without any medical or surgical intervention were included in the study. The study subjects were divided into two groups: 50 received oral glycopyrronium bromide, and 50 received oral trihexyphenidyl. Glycopyrronium bromide was administered starting at 0.02 mg/kg three times daily, titrated up to 0.1 mg/kg. Trihexyphenidyl was administered starting at 1 mg daily, increasing to a maximum of 2 mg three times a day. Follow-ups were conducted at 1, 3, and 6 months to assess drooling severity and frequency using the Thomas Stonell and Greenberg drooling rating scale.

Results: Glycopyrronium bromide was found to be more effective at 3 months in terms of only frequency (p= 0.02) but in terms of severity, which was statistically not significant. And at 6 months in terms of both frequency (p=0.00.9) and severity (p=0.001) of drooling was significantly improved with glycopyrronium bromide in comparison to trihexyphenidyl.

Conclusion: Oral glycopyrronium bromide was found to be significantly more effective than trihexyphenidyl at 3 months and 6 months to reduce drooling in children with cerebral palsy and side effects of both drugs are almost similar.

J Bangladesh Coll Phys Surg 2026; 44: 11-16

Downloads

Download data is not yet available.
Abstract
2
PDF
0

Downloads

Published

2026-02-01

How to Cite

Happy, R. A., Debnath, B., Saha, N. C., Hoque, S. A., Begum, M. S. A., Quiraishi, S. A., … Sultana, T. (2026). Glycopyrronium Bromide is superior to Trihexyphenidyl for reducing drooling in children with cerebral palsy—An unregistered randomized controlled trial. Journal of Bangladesh College of Physicians and Surgeons, 44(1), 11–16. https://doi.org/10.3329/jbcps.v44i1.87292

Issue

Vol. 44 No. 1 (2026)

Section

Original Articles

License

Submission of a manuscript for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted manuscripts become the permanent property of the Journal of Bangladesh College of Physicians and Surgeons and may not be reproduced by any means in whole or in part without the written consent of the publisher.

No part of the materials published in this journal may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher. Reprints of any article in the Journal will be available from the publisher.